Claims
- 1. A compound of Formula (I)
- 2. A compound according to claim 1 wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 3. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 4. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 5. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 6. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 7. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 8. A compound according to claim 1 wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 9. The compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 10. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 11. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 12. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 13. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 14. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 15. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 16. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 17. A compound according to claim 1, wherein Z is —NH—, n is O, X is aryl and A″ is the moiety
- 18. The compound of claim 1, which is 9-(3-Chloro-4-fluoroanilino)-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 19. The compound of claim 1, which is 1-[(2E)-4-Chloro-2-butenoyl]-9-(3-chloro-4-fluoroanilino)-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 20. The compound according to claim 1, which is 1-[(2E)-4-Bromo-2-butenoyl]-9-(3-chloro-4-fluoroanilino)-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 21. The compound according to claim 1, which is 9-(3-Chloro-4-fluoroanilino)-1-[(2E)-4-(dimethylamino)-2-butenoyl]-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-g-carbonitrile or a pharmaceutically acceptable salt thereof.
- 22. The compound according to claim 1, which is 9-(3-Chloro-4-fluoroanilino)-1-[4-(dimethylamino)butanoyl]-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 23. The compound according to claim 1, which is 1-(4-Chlorobutyl)-9-(3-chloro-4-fluoroanilino)-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 24. The compound according to claim 1, which is 9-(3-Chloro-4-fluoroanilino)-1-[4-(dimethylamino)butyl]-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 25. The compound according to claim 1, 9-(2,4-Dichloroanilino)-3,4-dihydro-2H-[1,4]oxazino[2,3-g]quinoline-8-carbonituile or a pharmaceutically acceptable salt thereof.
- 26. The compound according to claim 1, 4-(4-Chlorobutyl)-9-(2,4-dichloroanilino)-3,4-dihydro-2H-[1,4]oxazino[2,3-g]quinoline-8-carbonitrile or a pharmaceutically acceptable salt thereof.
- 27. The compound of claim 1, which is 9-(2,4-Dichloroanilino)-4-[4-(4-ethyl-1-piperazinyl)butyl]-3,4-dihydro-2H-[1,4]oxazino[2,3-g]quinoline-8-carbonitrile, or a pharmaceutically acceptable salt thereof.
- 28. A method of treating, inhibiting the growth of, or eradicating a neoplasm in a mammal in need thereof which comprises providing to said mammal an effective amount of a compound of Formula (I)
- 29. The method according to claim 28 wherein the neoplasm is selected from the group consisting of breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, lung, pancreas, liver, prostate, brain and skin.
- 30. The method according to claim 28 wherein the neoplasm expresses EGFR or erbB2(Her2).
- 31. The method according to claim 28 wherein the neoplasm depends, as least in part, on the MAPK pathway.
- 32. The method of claim 28 wherein the neoplasm depends, at least in part, on the ECK/LERK-1 pathway.
- 33. The method according to claim 28 wherein the neoplasm depends, at least in part, on the VEGF/KDR pathway.
- 34. The method of claim 28 wherein the neoplasm expresses Src or wherein the neoplasm depends at least in part on the Src pathway.
- 35. The method of claim 28 wherein the neoplasm expresses raf or wherein the neoplasm depends at least in part on the raf pathway.
- 36. The method of claim 28 wherein the neoplasm expresses EGFr, erbB-2, erbB-3 or erbB-4 or wherein the neoplasm depends at least in part on the EGFr, erbB-2, erbB-3 or erbB-4 pathway.
- 37. The method of claim 28 wherein the neoplasm expresses KDR or flt-1 or wherein the neoplasm depends at least in part on the KDR or flt-1 pathway.
- 38. The method of claim 28 wherein the neoplasm expresses PDGFr or wherein the neoplasm depends at least in part on the PDGFr pathway.
- 39. The method of claim 28 wherein the neoplasm expresses FGFr or wherein the neoplasm depends at least in part on the FGFr pathway.
- 40. The method of claim 28 wherein the neoplasm expresses tie-1 or tie-2 or wherein the neoplasm depends at least in part on the tie-1 or tie-2 pathway.
- 41. The method of claim 28 wherein the neoplasm expresses EPH or wherein the neoplasm depends at least in part on the EPH pathway.
- 42. The method of claim 28 wherein the neoplasm expresses a non-receptor tyrosine kinase including Abl, Jak, Fak, Syk or Csk or wherein the neoplasm depends at least in part on the Abl, Jak, Fak, Syk or Csk pathway.
- 43. The method of claim 28 wherein the neoplasm expresses mek or erk or wherein the neoplasm depends at least in part on the MAPK pathway.
- 44. The method of claim 28 wherein the neoplasm expresses a cyclin dependent kinase or wherein the neoplasm depends at least in part on a cyclin dependent kinase pathway.
- 45. The method of claim 28 wherein the neoplasm expresses a Src family kinase including Yes, Lck or Lyn or wherein the neoplasm depends at least in part on a Src family kinase pathway.
- 46. The method of claim 28 wherein the neoplasm expresses PKA, PKB or PKC or wherein the neoplasm depends at least in part on a PKA, PKB or PKC pathway.
- 47. A method of treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a compound of Formula (I)
- 48. A method of treating, inhibiting, or eradicating colonic polyps in a mammal in need thereof which comprises providing to said mammal an effective amount of a compound of Formula (I)
- 49. A method of inhibiting the biological effects of a deregulated protein kinase in a mammal which comprises providing to said mammal an effective amount of a compound of Formula (I)
- 50. A method of treating a disease or inhibiting a disease state whose etiology is at least in part caused by a defect in a signaling pathway upstream from a protein kinase; by overexpression of a protein kinase; or by a dysregulated protein kinase in a mammal in need thereof which comprises providing to said mammal an effective amount of a compound of Formula (I),
- 51. A method of treating or inhibiting the progression of restenosis in a mammal in need thereof which comprises providing to said mammal an effective amount of a PDGFr kinase inhibitor of Formula (I),
- 52. A method of treating, inhibiting or eradicating autoimmune diseases which include rheumatoid arthritis, sepsis and transplant rejection in a mammal in need thereof which comprises providing to said mammal an effective amount of a Zap-70 or Lck kinase inhibitor of Formula (I),
- 53. A method of treating, inhibiting or eradicating viral infections in a mammal in need thereof which comprises providing to said mammal an effective amount of a UL-97 kinase inhibitor of Formula (I)
- 54. A method of treating or inhibiting the progression of osteoporosis in a mammal in need thereof which comprises providing to said mammal an effective amount of a Src kinase inhibitor of Formula (I),
- 55. A pharmaceutical composition comprising a compound of Formula (I)
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. (To be Assigned) which was converted from U.S. patent application Ser. No. 09/536,919 filed Mar. 28, 2000 pursuant to a petition filed under 37 C.F.R. 1.53 (c) (2) filed Jul. 11, 2000.